Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 45.00 |
Expiry date | 2024-05-17 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 309 |
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees. These inducement RSUs are subjec
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
Insights into revenue growth, strategic expansions, and challenges faced in the first quarter of 2024.